Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )

NCT04432454 is registered in ClinicalTrials.gov with Sermonix Pharmaceuticals Inc. as lead sponsor.

NCT NCT04432454
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04432454 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination With Abemaciclib for the Treatment of Pre- and Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and Have an ESR1 Mutation ( ELAINEII )
Lead sponsor
Sermonix Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 29, 2020
Completion date
January 28, 2025
Enrollment
29 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer